Enphase Energy faces near-term headwinds, including weak Q3 2025 guidance and market share losses. Read why I rate ENPH stock ...

Discover why Enphase Energy (ENPH) is now rated Buy despite recent declines. Learn how IRA credits and cash reserves could ...

Phio Pharmaceuticals shares were higher after the company reported positive pathology results for its Phase 1b Intasyl PH-762 trial. The stock was 32% higher, at $2.72. Shares are up 55% year to date.

About Anavex Life Sciences Corp. Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of ...